Skip to content
DataLookout
Menu

NCT03775265

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 684 versions: 10 with changes below, 40 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion date changed from estimate of Jun 1, 2027 to Jul 23, 2026
    • Study completion pushed from Jun 1, 2027 to Nov 13, 2027
    • Enrollment target: estimated 475 to confirmed 485
  2. Notable Eligibility criteria expanded, about 57 words
    • Secondary endpoints: details revised at 5 of 8 entries
    • Study description revised
    • Site details revised at 23 of 365 sites
  3. Minor Study sites: 366 to 365v680
  4. Minor Study sites revised (366)v679
  5. Minor Study sites revised (366)v677
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Study sites revised (366)v676
  2. Minor Site details revised at 1 of 366 sitesv675
  3. Minor Study sites revised (366)v674
  4. Minor Study sites revised (366)v673
  5. Minor Site details revised at 1 of 366 sitesv672
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Bladder intact event-free survival (BI-EFS)
Timeframe: From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years

Secondary (8)

Overall survival (OS)
Modified bladder intact event-free survival (mBI-EFS)
Biopsy response
Complete response duration
Progression-free survival
Show 3 moreShow less
Metastasis-free survival
Cancer-specific survival
Quality of life

Arms and interventions

Arm I (RT, chemotherapy)Active comparator

Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.

Arm II (RT, chemotherapy, atezolizumab)Experimental

Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.

Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin

Procedures: Biopsy of Bladder, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor

Other: Quality-of-Life Assessment, Survey Administration

Radiation: Radiation Therapy

Sites

365 sites in 1 country